433331-90-9

Upstream product

• 360775-63-9 methyl 4-(4-ethylbenzyl)-3-hydroxybenzoate 
• 100-39-0 benzyl bromide 
• 24589-98-8 methyl 4-formyl-3-hydroxybenzoate 
• 1585-07-5 1-bromo-4-ethylbenzene 
• 360776-08-5 C₁₇H₁₈O₄ 
• 1005487-66-0 3-benzyloxy-4-(4-ethylbenzyl)benzyl acetate 

Downstream Products

• 433331-91-0 [3-Benzyloxy-4-(4-ethylbenzyl)phenyl]acetonitrile 
• 433331-94-3 2-[4-(4-Ethylbenzyl)-3-hydroxyphenyl]acetoamide 
• 433331-93-2 [3-benzyloxy-4-(4-ethylbenzyl)phenyl] acetic acid 
• 433331-92-1 2-[3-Benzyloxy-4-(4-ethylbenzyl)phenyl]acetoamide 
• 1005487-67-1 3-benzyloxy-4-(4-ethylbenzyl)benzaldehyde 

Relevant academic research and scientific papers

BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE

The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): wherein R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, provided that R5, R6, R7 and R8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.

GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF

The present invention provides glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein P represents a hydrogen atom or a group forming a prodrug; R1 represents a hydrogen atom, an optionally substituted amino grou

GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF

The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.